期刊文献+

急性非淋巴细胞白血病MEA方案诱导缓解第7天追加化疗的疗效观察 被引量:3

原文传递
导出
摘要 目的探讨应用MEA方案(米托蒽醌+足叶乙甙+阿糖胞苷)诱导缓解治疗急性非淋巴细胞白血病(ANLL)第7天追加化疗的疗效观察。方法采用MEA方案治疗初诊ANLL患者60例后,分为第7天追加化疗的治疗组(A组)28例和对照组(B组)32例,疗程结束后再次复查骨髓象,进行疗效评价。结果 A组CR率高于B组(82.1% vs. 56.3%)(P<0.05)。A组较B组粒细胞缺乏持续时间和发热持续时间延长(P<0.05)。两组在恶心、呕吐发生率,肝脏、心脏损害发生率及诱导治疗相关死亡率均无统计学差异。结论 MEA方案作为初诊ANLL一线治疗方案可取得良好疗效。
出处 《江苏医药》 CAS CSCD 北大核心 2012年第24期2997-2999,共3页 Jiangsu Medical Journal
基金 国家自然科学基金(81170489) 江苏省自然科学基金(BK2010287)
  • 相关文献

参考文献5

  • 1李玉峰,潘文友,钱墨生.MEA方案在成人急性非淋巴细胞白血病诱导治疗中的疗效观察[J].中华血液学杂志,1999,20(2):108-108. 被引量:7
  • 2Mehayleh W, Sehgal R, Redner RL, et al. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin[J]. Leuk Lymphoma, 2009,50 (11):1848-1853.
  • 3Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10[J]. J Clin Oneol,2009,27(32) :5397-5403.
  • 4Lofgren C, Paul C, AstrOm M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial[J]. Br J Haematol, 2004,124 (4) : 474-480.
  • 5Styczynski J, Pieters R, Huismans DR, et al. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia[J]. Br J Haernatol, 2000, 110 (4) : 813-818.

共引文献6

同被引文献27

  • 1郑君议,陈建斌.米托蒽醌联合阿糖胞苷诱导治疗成人初治急性髓细胞性白血病疗效分析[J].重庆医学,2005,34(9):1301-1303. 被引量:5
  • 2Vousden K H,LU X. Live or let die:the cell's response to p53[J]. Nat Rev Cancer, 2002,2(8) : 594-604.
  • 3Chipuk J E, Green D R. Dissecting p53-dependent apoptosis[J]. Cell Death Differ, 2006,13(6) : 994-1002.
  • 4De Vries A,Flores E R,Miranda B,et al. Targeted point muta tions of p53 lead to dominant-negative inhibition of wild-type p53 funetion[J]. Proe Natl Acad Sei U S A,2002,99(5) ..2948- 2953.
  • 5Walker D R,Bond J P,Tarone R E,et al. Evolutionary conser- vation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features[J]. Oneo- gene, 1999,18(1) :211-218.
  • 6Melo M B,Ahmad N N,Lima C S,et al. Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis[J]. Hematology, 2002,7 (1): 13-19.
  • 7Pavlova S, Mayer J, Koukalova H, et al. High frequency of tempera- ture-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast [J]. Int J Oncol, 2003,23(1):121-131.
  • 8Nakano Y, Naoe T, Kiyoi H, et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia[J]. Eur J Haematol,2000,65(1) :23-31.
  • 9Chiaretti S, Brugnoletti F, Tavolaro S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases nega- tive for recurrent fusion genes and correlate with poor re- sponse to induction therapy[J]. Haematologica, 2013,98 ( 5 ) : e59-e61.
  • 10张之南,沈悌.血液病诊断及疗效标准tM].北京:北京科学技术出版社,2007.131-134.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部